

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**北 斗 嘉 藥 業 股 份 有 限 公 司**

**BAYTACARE PHARMACEUTICAL CO., LTD.\***

*(formerly known as 東北虎藥業股份有限公司(Northeast Tiger Pharmaceutical Co., Ltd.\*))*

*(a joint stock limited company incorporated in the People's Republic of China)*

**(Stock Code: 8197)**

**CHANGE OF AUTHORISED REPRESENTATIVE**

Reference is made to the announcement of Baytacare Pharmaceutical Co., Ltd.\* (formerly known as Northeast Tiger Pharmaceutical Co., Ltd.\*) (the “**Company**”) dated 31 May 2017 in relation to, among others, the poll results of the annual general meeting of the Company held on 31 May 2017 (the “**AGM**”) and the change of directors (the “**Directors**”) of the Company (the “**Announcement**”).

As disclosed in the Announcement, Mr. Qin Haibo (秦海波) (“**Mr. Qin**”) has ceased to be an executive Director with effect from the close of the AGM on 31 May 2017. The board (the “**Board**”) of Directors hereby announces that Mr. Qin has also ceased to be an authorised representative of the Company under Rule 5.24 of the Rules Governing the Listing of Securities on the Growth Enterprise Market (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from the close of the AGM on 31 May 2017.

The Board further announces that Ms. Cui Bingyan (崔冰岩) (“**Ms. Cui**”), an executive Director, has been appointed as an authorised representative of the Company under Rule 5.24 of the GEM Listing Rules with effect from 18 July 2017.

As at the date of this announcement, the authorised representatives of the Company under Rule 5.24 of the GEM Listing Rules are Mr. Wang Shaoyan (王少岩) and Ms. Cui.

By Order of the Board  
北斗嘉藥業股份有限公司  
**Baytacare Pharmaceutical Co., Ltd.\***  
*Chairman*  
**Wang Shaoyan**

Jilin, the People's Republic of China, 18 July 2017

*As at the date of this announcement, the executive Directors are Wang Shaoyan, Cui Bingyan and Jiang Xiaobin; the non-executive Directors are Shi Peng and Cao Yang and the independent non-executive Directors are Hui Lai Yam, Gao Zhikai and Yang Yulin.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the website of the Growth Enterprise Market of the Stock Exchange at <http://www.hkgem.com> for at least 7 days from the day of its posting and the Company’s website at <http://www.baytacare.com> from the date of this announcement.*

*\* For identification purpose only*